Search results
13 mar 2018 · Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors.
- Basic information about memantine and its treatment of Alzheimer's ...
Memantine is a noncompetitive moderate‐affinity strong...
- Dementia Prevention and Treatment: A Narrative Review
Alzheimer disease can be treated with cholinesterase...
- Memantine: efficacy and safety in mild-to-severe Alzheimer’s disease
Memantine, an NMDA receptor antagonist has been found to be...
- Memantine for the Treatment of Dementia: A Review on its ... - PubMed
Memantine (MEM), an antagonist of extrasynaptic NMDAR, is...
- Memantine for Alzheimer's Disease: An Updated Systematic ... - PubMed
The meta-analyses suggest the credible efficacy and safety...
- Basic information about memantine and its treatment of Alzheimer's ...
6 cze 2023 · Memantine is a noncompetitive moderate‐affinity strong voltage‐dependent N‐methyl‐D‐aspartate receptor antagonist. It has been used to treat Alzheimer's disease (AD) since 1989. In 2018, it became the second most commonly used drug for the treatment of dementia in the world.
1 maj 2024 · Alzheimer disease can be treated with cholinesterase inhibitors, memantine, and antiamyloid immunomodulators, with the last modestly slowing cognitive and functional decline in people with mild cognitive impairment or mild dementia due to Alzheimer disease.
2 mar 2007 · Memantine, an NMDA receptor antagonist has been found to be effective, both as monotherapy and in combination with donepezil, in the treatment of patients with moderate to severe stage AD.
Memantine (MEM), an antagonist of extrasynaptic NMDAR, is currently used for the treatment of AD jointly with acetylcholinesterase inhibitors.
The meta-analyses suggest the credible efficacy and safety of memantine in treating AD when used alone or in combination with ChEIs.
Alzheimer disease can be treated with cholinesterase inhibitors, memantine, and antiamyloid immunomodulators, with the last modestly slowing cognitive and functional decline in people with mild cognitive impairment or mild dementia due to Alzheimer disease.
